APR 002
Alternative Names: APR-002Latest Information Update: 28 Oct 2023
At a glance
- Originator Apros Therapeutics
- Developer Apros Therapeutics; Global Health Drug Discovery Institute
- Class Antivirals; Small molecules
- Mechanism of Action Toll-like receptor 7 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase 0 COVID 2019 infections
- No development reported Hepatitis B
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Hepatitis-B in USA (PO)
- 29 Jun 2023 Apros Therapeutics completes a phase 0 for COVID-2019 infections (In volunteers) in Australia (Inhalation) (NCT05268198)
- 16 Feb 2023 Phase-0 for COVID-2019 infections (In volunteers) in Australia (Inhalation) (NCT05268198)